Measuring redox changes in plasma proteins
AssigneeCancer Research Technology Limited
InventorsSara Rossana Zanivan, Sergio Lilla, Ulla-Maja Hagbo Bailey
Life of this patent
Estimating the term…
Loading patent…
AssigneeCancer Research Technology Limited
InventorsSara Rossana Zanivan, Sergio Lilla, Ulla-Maja Hagbo Bailey
Estimating the term…
Provided is a method for measuring proteomic cysteine redox status in a sample obtained from a bodily fluid of a subject, the method comprising: (i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form; (ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins; (iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols; (iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry, (v) processing the sample for analysis by mass spectrometry; and (vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample. The invention also provides related methods for biomarker discovery and for predicting presence of a liver disease and/or cancer, such as hepatocellular carcinoma (HCC) in a subject.
A method for measuring proteomic cysteine redox status in a sample obtained from bodily fluid of a subject, the method comprising:
The method of any one of the preceding claims, wherein said sample is heated to a temperature of greater than 50° C., optionally greater than 90° C., for a period of time sufficient to increase protein denaturation prior to or current with contacting the sample with said first label.
The method of any one of the preceding claims, wherein said first label is selected from:
The method of any one of the preceding claims, wherein said second label is selected from:
The method of any one of the preceding claims, wherein said first label comprises IAA-light and said second label comprises IAA-heavy.
The method of any one of the preceding claims, wherein said reducing agent comprises dithiothreitol (DTT).
The method of any one of the preceding claims, wherein said sample is solubilised by contacting with sodium deoxycholate (SDC) prior to or during step (ii).
The method of any one of the preceding claims, wherein said sample is contacted with magnetic beads, optionally SpeedBead Magnetic Carboxylate (SP3 beads), prior to or during step (v).
The method of any one of the preceding claims, wherein the method further comprises contacting the sample with at least one tandem mass tag (TMT) to enable multiplexing of said mass spectrometry analysis.
The method of any one of the preceding claims, wherein the concentration of said second label in step (iv) is higher than the concentration of said first label in step (ii).
The method of any one of the preceding claims, wherein said processing of step (v) comprises at least one of:
The method of any one of the preceding claims, wherein the mass spectrometry (MS) comprises ultra-high performance liquid chromatography-MS/MS (UHPLC-MS/MS).
The method of any one of the preceding claims, wherein step (vi) further comprises calculating, for each of a plurality of cysteine residues, the proportion that was in reversibly oxidised form in the sample.
The method of any one of the preceding claims, wherein step (vi) further comprises deriving at least one statistical measure, optionally a z-score, for the degree of cysteine oxidation of each of a plurality of non-identical peptides.
The method of any one of the preceding claims, wherein said plurality of different proteins comprises at least 50, 100, 500, or at least 1000.
The method of any one of the preceding claims, wherein said sample is of less than 100 μl, less than 50 μl, less than 10 μl, less than 1 μl or less than 100 nl when obtained from the subject.
The method of any one of the preceding claims, wherein the method further comprises normalising the measure of identified peptides labelled with the first label and/or the measure of identified peptides labelled with the second label for protein abundance.
Dependencies are inferred from the claim text.